A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

Launched by MERCK SHARP & DOHME LLC · Sep 20, 2024

Keywords

ClinConnect Summary

This clinical trial, called V118C-001, is studying a new vaccine called V118 Formulation C (V118C) to see how safe it is for healthy adults. The main goal is to find out how well people tolerate this vaccine, meaning how their bodies react to it without experiencing serious side effects. The trial is currently looking for participants who are between the ages of 65 and 74 and are generally in good health.

To be part of this study, participants need to be healthy and without any significant medical issues. For example, individuals with a history of certain infections or serious health conditions affecting their organs or immune system may not be eligible. Those who join the trial can expect to receive the vaccine and will be monitored closely for their reactions. This research is important because it helps scientists understand how safe the vaccine is before it is given to more people.

Gender

ALL

Eligibility criteria

• The main inclusion criteria include but are not limited to the following:
• • Is in good health before randomization
• Exclusion Criteria:
• • Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination.
• • Has a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.